Targeted Therapy with CRISPR Engineered Human Hematopoietic Stem Cells

Introduction

Human hematopoietic stem cells (HSCs) are rare, multipotent, self-renewing cells responsible for the lifelong production of all mature blood and immune cell types. Located primarily in specialized bone marrow niches, HSCs maintain hematopoietic homeostasis by continuously generating erythrocytes, platelets, and diverse leukocyte populations that are essential for oxygen transport, hemostasis, and immune defense. Because mature blood cells are generally short-lived, the regenerative activity of HSCs is indispensable for survival. Importantly, the position of HSCs at the apex of this hierarchy makes them uniquely attractive targets for genetic modification. Editing the genome of HSCs allows stable, systemic, and potentially lifelong modification of all downstream blood lineages, offering unprecedented opportunities for the treatment of inherited genetic diseases, cancer, infectious disease, and immunological complications such as transplant rejection.

Biology of Hematopoietic Stem Cells and Lineage Commitment

HSCs are defined functionally by their ability to self-renew and to reconstitute the entire hematopoietic system following transplantation. These properties reflect a tightly regulated balance between quiescence, proliferation, and differentiation controlled by intrinsic transcriptional programs and extrinsic cues from the bone marrow microenvironment, including cytokines, growth factors, and cell–cell interactions. Upon activation, HSCs generate multipotent progenitor cells that retain multilineage differentiation capacity but lack long-term self-renewal. These progenitors progressively restrict their fate through a series of lineage decisions, culminating in the production of committed myeloid or lymphoid progenitors.

The myeloid branch produces erythroid progenitors that generate red blood cells, megakaryocytic progenitors that give rise to platelets, and granulocyte–monocyte progenitors that form neutrophils, eosinophils, basophils, and monocytes. The lymphoid branch generates B lymphocytes, T lymphocytes, and natural killer cells, which mediate adaptive and cytotoxic immunity. This hierarchical architecture enables precise quantitative and qualitative control over blood cell production while preserving a small pool of long-lived HSCs capable of sustaining hematopoiesis throughout life.

CRISPR-Mediated Editing of HSCs as a Therapeutic Strategy

CRISPR technology enables precise targeting of genomic sequences within HSCs through a guide RNA (gRNA) that directs the Cas nuclease to a specific DNA locus. Cas9 or alternative CRISPR effectors introduce double-strand breaks (DSBs) or base modifications that cells repair via endogenous pathways.

Because HSCs generate all blood and immune cells, genetic modification at the HSC level enables durable reprogramming of the hematopoietic system. Editing an HSC ensures that all of its progeny inherit the engineered genetic change, resulting in long-term or lifelong therapeutic effects. This approach contrasts with therapies targeting mature blood cells, which are transient and require repeated administration.

Process for CRISPR-Mediated Genetic Modification of HSCs

CRISPR-mediated modification of autologous human hematopoietic stem cells is a multistep process that integrates clinical cell procurement, ex vivo genome engineering, and autologous transplantation to achieve durable genetic correction of the hematopoietic system. The overall workflow comprises HSC collection, purification, genome editing, expansion, patient conditioning, reinfusion, and post-transplant hematopoietic reconstitution.

Bone Marrow Collection or Mobilized Peripheral Blood Harvest

• Patients receive granulocyte colony-stimulating factor, to mobilize HSCs from the bone marrow into the bloodstream. Leukapheresis is then performed to collect peripheral blood mononuclear cells enriched for HSCs.

Isolation and Purification of HSCs

• Collected cells are enriched for HSCs using immunomagnetic separation or flow cytometry sorting, typically selecting using the HSC marker CD34. Additional markers may be used to further enrich for long-term repopulating HSCs. The purified CD34⁺ cell population serves as the substrate for genome editing.

CRISPR Delivery and Genome Editing

• Genome editing is performed ex vivo using CRISPR systems delivered primarily as ribonucleoprotein complexes consisting of recombinant Cas nuclease pre-complexed with a synthetic guide RNA. For precise sequence correction or gene insertion, a DNA repair template is co-delivered, commonly via adeno-associated virus serotype 6 or as single-stranded oligodeoxynucleotides, to promote homology-directed repair. The cells are exposed to CRISPR components by electroporation or nucleofection, which allows efficient intracellular delivery while preserving cell viability.

Ex Vivo Culture and Quality Control

• Edited HSCs are cultured short-term in serum-free, cytokine-supplemented media. Cells are not extensively expanded to avoid differentiation or loss of long-term repopulating capacity. Only cell products that meet a predefined release criteria are approved for clinical use.

Patient Conditioning

• Before reinfusion, patients undergo myeloablative treatment, typically with chemotherapy agents such as busulfan. Conditioning eliminates a portion of the endogenous hematopoietic compartment and creates space within the bone marrow niche, enabling efficient engraftment of the edited HSCs.

Re-Infusion of Edited HSCs

• The edited autologous HSCs are infused intravenously into the patient in a procedure analogous to standard hematopoietic stem cell transplantation. The cells home to the bone marrow, lodge in the stem cell niche, and initiate hematopoietic reconstitution.

Engraftment, Hematopoietic Reconstitution, and Recovery

• Following transplantation, patients experience a transient period of cytopenia until engraftment occurs. Over weeks to months, edited HSCs give rise to all major blood and immune lineages, establishing a genetically modified hematopoietic system.
• Successful engraftment results in durable, potentially lifelong therapeutic benefit derived from the self-renewal and multilineage differentiation capacity of genetically modified HSCs.

Potential Therapeutic Indications for CRISPR HSC Therapy

Inherited Genetic Diseases

• In inherited erythroid disorders such as sickle cell disease and β-thalassemia, genetic defects in hemoglobin structure or production lead to chronic anemia, organ damage, and reduced lifespan. Genetic modification of HSCs can correct these defects by repairing the causative mutation or by reactivating fetal hemoglobin expression, thereby producing erythrocytes resistant to sickling or deficient globin chain imbalance. The result is sustained production of functional red blood cells and amelioration of disease pathology.
• Primary immunodeficiencies such as severe combined immunodeficiency arise from mutations that impair lymphocyte development or function. Editing HSCs to restore these genes allows normal differentiation of T and B cells, reconstituting immune competence and protecting against life-threatening infections.
• Chronic granulomatous disease, caused by defects in neutrophil oxidative killing, can be treated by restoring NADPH oxidase function in HSCs, yielding neutrophils capable of effective microbial clearance.

Cancer

Cancer therapeutics utilizing CRISPR to modify HSCs are an emerging area. One avenue is to engineer HSCs to produce immune cells with enhanced anticancer activity. For example, HSCs can be modified to generate T cells expressing chimeric antigen receptors (CARs) targeting tumor-associated antigens, potentially yielding a self-renewing source of CAR-expressing cells for leukemia or solid tumors. Although most CAR therapies currently employ mature T cells, HSC editing supports long-term engraftment and sustained production of engineered immune cells. Clinical investigation of CRISPR-modified HSCs to treat hematologic cancers and enhance immune surveillance is ongoing, although such strategies remain largely in early-stage research rather than approved therapy at present.

Infectious Diseases

HIV infection has been a major target for CRISPR-mediated genetic therapy of HSCs. HIV uses the CCR5 chemokine receptor on the surface of immune cells as a coreceptor for entry. Individuals with the natural CCR5Δ32 mutation are resistant to R5-tropic HIV strains. Ex vivo CRISPR-Cas9 disruption of CCR5 in HSCs aims to produce descendant immune cells lacking functional CCR5, thereby conferring resistance to HIV entry and replication. Preclinical models and early clinical investigations have shown that CCR5-ablated HSCs can engraft and generate HIV-resistant lineages, providing proof of concept for this approach.

Transplantation Rejection and Immune Modulation

Engineering HSCs to promote immune tolerance, for example by enhancing regulatory T cell development or reducing alloreactivity, can facilitate acceptance of transplanted organs or tissues while preserving protective immunity.

CRISPR-edited HSCs to prevent allograft rejection are not yet mature, conceptually HSCs can be engineered to promote immune tolerance. For example, editing HLA genes or immune checkpoint regulators in donor HSCs might reduce alloimmune recognition and mitigate graft-versus-host disease (GVHD) while preserving beneficial graft-versus-tumor effects.

Studies investigating CRISPR editing of donor tissues (e.g., kidneys) to reduce immunogenicity demonstrate the translational potential of gene editing in transplant biology.

Investigational CRISPR-Edited HSC Therapies

The table below summarizes a representative set of investigational and emerging therapies that employ CRISPR-based genome editing of human hematopoietic stem cells (HSCs) to treat a diverse range of genetic, infectious, oncologic, and immunologic diseases. These approaches exploit the self-renewal capacity and multilineage differentiation potential of HSCs to enable durable, system-wide therapeutic effects following a single intervention. While the first clinical successes have been achieved in hemoglobinopathies through disruption of the fetal hemoglobin repressor pathway, the field has rapidly expanded toward broader applications including viral resistance (e.g., CCR5 and CXCR4 editing for HIV), immune reconstitution in primary immunodeficiencies, leukemia relapse prevention, transplantation tolerance via HLA engineering, and safety-enhanced gene and cell therapies incorporating genetic control circuits. Collectively, these programs illustrate the versatility of CRISPR platforms, including nuclease editing, base editing, and emerging in vivo delivery strategies, in reshaping HSC genomes for therapeutic benefit, and they highlight the transition of genome editing from proof-of-concept to a clinically actionable modality.

Table 1: CRISPR-Edited HSC Therapeutic Program Examples

Together, the examples in this table underscore the rapid maturation and diversification of CRISPR-edited HSC therapies from early experimental systems into clinically relevant interventions. Although most programs remain in preclinical or early-phase development, they demonstrate that precise genetic modification of HSCs can be leveraged to correct inherited disorders, confer resistance to infectious pathogens, enhance anti-cancer immunity, and improve the safety and accessibility of cellular therapies. The convergence of improved editing technologies, safer delivery systems, and expanding biological insight into HSC regulation is accelerating the translation of these approaches into the clinic. As regulatory experience grows and long-term safety data accumulates, CRISPR-engineered HSCs are poised to become a foundational platform for durable, potentially curative treatments across a wide spectrum of human disease.

Clinically Approved Exagamglogene Autotemcel (CASGEVY™ / exa-cel) for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) are inherited hemoglobinopathies characterized by defective β-globin synthesis that lead to profound clinical morbidity. SCD arises from a point mutation (β^S) in the β-globin gene causing hemoglobin polymerization, red blood cell sickling, vaso-occlusive crises (VOCs), hemolysis, and chronic organ damage. TDT results from mutations that severely reduce or abolish β-globin production, causing ineffective erythropoiesis, profound anemia, and lifelong dependence on blood transfusions with associated iron overload and complications. Both disorders significantly impair quality of life and longevity.

Exagamglogene autotemcel is a one-time, autologous HSC therapy that employs CRISPR/Cas9 gene editing to disrupt an erythroid-specific enhancer of BCL11A, a transcription factor that represses fetal hemoglobin (HbF) expression. By precisely introducing a double-strand break in this enhancer region, BCL11A expression in erythroid cells is reduced, thereby reactivating γ-globin and increasing HbF production.

The primary therapeutic aim is durable, high-level HbF expression that ameliorates the pathogenic consequences of defective β-globin.

In SCD, higher HbF reduces intracellular sickle hemoglobin polymerization and prevents RBC sickling and VOCs. Successful treatment should eliminate or drastically reduce VOCs and hospitalization due to pain crises.

In TDT, increased HbF helps correct the α/β imbalance, reducing ineffective erythropoiesis. The goal is transfusion independence with sustained hemoglobin levels sufficient to avoid chronic transfusions.  A single administration of CRISPR modified HSC with long-term benefit is the intended outcome, representing a functional cure for patients.

Exagamglogene autotemcel (CASGEVY™/exa-cel) represents a landmark in genomic medicine: the first approved CRISPR/Cas9 gene-edited HSC therapy for monogenic blood disorders. By reactivating fetal hemoglobin through targeted editing of the BCL11A enhancer, exa-cel addresses fundamental pathobiological mechanisms in SCD and TDT. Clinical trials have shown transformative efficacy with durable clinical benefit, including near-universal freedom from VOCs in SCD and high rates of transfusion independence in TDT, with safety profiles aligned with established autologous transplant procedures. As long-term follow-up continues, exa-cel is poised to redefine standards of care for these debilitating diseases.

Conclusion

Human hematopoietic stem cells are the foundational source of all blood and immune cells, offering an unparalleled platform for therapeutic genetic modification. The advent of CRISPR technology has catalyzed a new era in precision medicine by enabling targeted editing of HSC genomes with unprecedented accuracy and efficiency. Clinically, CRISPR-mediated editing of HSCs is already transforming the treatment of inherited hemoglobinopathies, with therapies such as exagamglogene autotemcel achieving regulatory approval and delivering durable, life-altering benefits for patients with sickle cell disease and transfusion-dependent β-thalassemia. Beyond hemoglobinopathies, CRISPR strategies targeting HIV resistance and novel gene correction approaches continue to emerge from early clinical studies, highlighting the broad applicability of CRISPR-edited HSCs to genetic diseases, cancer immunotherapy, infectious diseases, and immune modulation for transplantation.

As CRISPR methodologies evolve, including improvements in homology-directed repair, base editing, and prime editing, the scope of treatable conditions is expected to expand. Continued clinical evaluation, long-term safety monitoring, and refinement of delivery and editing platforms will be crucial for realizing the full therapeutic potential of CRISPR-modified HSCs in both rare and common diseases.

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)

• ADME/Tox
• Molecular Biology
• The Art of Cell Culture
• Exosomes
• Stability Services
• Potency Assay
• Gene Therapy Assays
• Immunotherapy Assays
• Antiviral Therapy Assays
• cGMP
• MLR
• Cell Based Assays
• ELISA
• Flow Cytometry
• Protein
• PCR-qPCR
• Immunoassay
• Radioimmunoassay
• GLP
• Transfection
• Cell Therapy Assays
• Targeted Protein Degradation
• Research to Commercialization